Interestingly, this group also observed that elevated levels of PAR identified in PARP1-overexpressing tumor cells and xenografts predicted response to PARP inhibition in vitro and in vivo more accurately than PARP1 expression itself, suggesting PAR may be a reasonable biomarker of response to PARP inhibitor therapy in cervical cancer. Here, PARP1 is linked to neoplasm.